About Pathology IMC

The Immune Monitoring Core (IMC) offers a range of services to the UF research community and collaborators, including cutting edge technologies, high end instrumentation, and technical support and expertise in specialized equipment or processes. IMC will serve as a critical infrastructure to facilitate the overall research, service, and educational missions of the institution. The data from the services will result in research publications to accelerate the core research mission of UF and College of Medicine.

The University of Florida has conducted pioneering research into a host of diseases impacting human health. These efforts include studies to identify the underlying molecular pathways controlling diseases and the development of biomarkers of disease and/or therapeutic responses. These discoveries are made possible by the use of standardized precision medicine approaches accounting for patient heterogeneity and unique gene expressions. These precise and targeted approaches to study the candidate genes involved disease pathogenesis will serve the UF search communities as critical infrastructure to facilitate the overall research, service, and educational mission of the institution.

Faculty Director

Dr. Todd Brusko

Dr. Todd Brusko oversees key efforts toward building research and equipment infrastructure to ensure cutting-edge research within the UFDI as well as expansion of research partnerships between UFDI faculty and industry.

Scientific Director

Dr. Daniel Perry

Dr. Daniel Perry directs IMC’s comprehensive immunophenotying, genotyping, single-cell sequencing (transcriptome, antigen receptors, epigenome), and various types of immunoassays.

Research Project Manager

Thinzar Pe Myint

Ms. Myint provides administrative management and acts as a liaison between IMC customers and IMC directors to achieve optimal performance in quality and efficiency.

Mobile Phone: 301-606-0251. Email: thinzar.myint@ufl.edu

 

Publications from IMC

Williams MD, Bacher R, Perry DJ, Grace CR, McGrail KM, Posgai AL, Muir A, Chamala S, Haller MJ, Schatz DA, Brusko TM, Atkinson MA, Wasserfall CH. Genetic Composition and Autoantibody Titers Model the Probability of Detecting C-Peptide Following Type 1 Diabetes Diagnosis. Apr 2021. Diabetes. 70(4):932-943. PMID: 33419759.

Japp AS*, Meng W*, Rosenfeld AM*, Perry DJ*, Thirawatananond P, Bacher RL, Liu C, Gardner JS, HPAP Consortium, Atkinson MA, Kaestner KH, Brusko TM, Naji A, Prak ETL, Betts MR. TCR+/BCR+ “double expresser” cells and their associated public B-cell clone are not enriched in type 1 diabetes. Feb 2021. Cell. 184(3):827-839. PMID: 33545036. (*co-first author)

Shapiro MR, Foster TP, Perry DJ, Rosenfeld RG, Dauber A, McNichols JA, Muir A, Hwa V, Brusko TM, Jacobsen LM. A Novel Mutation in Insulin-Like Growth Factor-1 Receptor (c.641-2A>G) Is Associated with Impaired Growth, Hypoglycemia, and Modified Immune PhenotypesHormone Research in Paediatric. Dec 2020. 93(5):322-334. PMID: 33113547.

Perry DJ*, Titov AA*, Sobel ES, Brusko TM, Morel L. Immunophenotyping reveals distinct subgroups of lupus patients based on their activated T cell subsets. Clin Immunol. 2020 Dec 29;221:108602. PMID: 33007439. (*co-first author)

Carr ALJ*, Perry DJ*, Lynam AL, Chamala S, Flaxman CS, Sharp SA, Ferrat LA, Jones AG, Beery ML, Jacobsen LM, Wasserfall CH, Campbell-Thompson ML, Kusmartseva I, Posgai A, Schatz DA, Atkinson MA, Brusko TM, Richardson SJ, Shields BM, Oram RA. Histological validation of a type 1 diabetes clinical diagnostic model for classification of diabetes. Diabet Med. 2020 Jul 7. [Epub ahead of print] PMID: 32634859. (*co-first author)

Beam CA, Wasserfall C, Woodwyk A, Akers M, Rauch H, Blok T, Mason P, Vos D, Perry D, Brusko T, Peakman M, Atkinson M. Synchronization of the Normal Human Peripheral Immune System: A Comprehensive Circadian Systems Immunology Analysis. Sci Rep. 2020 Jan 20;10(1):672. PMID: 31959869.

Perry DJ, Wasserfall CH, Oram RA, Williams MD, Posgai A, Muir AB, Haller MJ, Schatz DA, Wallet MA, Mathews CE, Atkinson MA, Brusko TM. Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling. Sci Rep. 2018 Mar 14;8(1):4529. PMID: 29540798.

Marcial GE, Ford AL, Haller MJ, Gezan SA, Harrison NA, Cai D, Meyer JL, Perry DJ, Atkinson MA, Wasserfall CH, Garrett T, Gonzalez CF, Brusko TM, Dahl WJ, Lorca GL. Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults. Front Immunol. 2017;8:655. eCollection 2017. PMID: 28659913.

Lowe JR, Perry DJ, Salama AK, Mathews CE, Moss LG, Hanks BA. Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer. 2016;4:89. eCollection 2016. PMID: 28031819.

Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA, Shuster JJ, Zou B, Wasserfall CH, Posgai AL, Mathews CE, Brusko TM, Atkinson MA, Schatz DA. Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes. Diabetes. 2016 Dec;65(12):3765-3775. Epub 2016 Sep 26. PMID: 27669730.